This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI) 30 days 90 days 365 days Advanced Chart Get SPPI alerts:Sign Up Key Stats Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More… Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Stock News HeadlinesBio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum DisordersJanuary 14, 2025 | prnewswire.comNon-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 4, 2024 | theglobeandmail.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 14, 2025 | Timothy Sykes (Ad)Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)October 2, 2024 | globenewswire.comNanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comSTALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in BiomedicinesJune 27, 2024 | globenewswire.comOsivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033June 25, 2024 | businesswire.comPneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 ConferenceMay 23, 2024 | globenewswire.comSee More Headlines SPPI Stock Analysis - Frequently Asked Questions How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.07. Read the conference call transcript. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF). Company Calendar Last Earnings11/10/2021Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SPPI CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:SPPI) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectrum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.